Cytokine‑induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

Li,Wei; Xu,Lin  Ping; Zhao,Ling  Di; Wang,Li; Zhang,Yong; Gao,Quan  Li; Mai,Ling

doi:10.3892/ol.2013.1200

April 2013 Volume 5 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April 2013 Volume 5 Issue 4

Full Size Image

Case Report

Cytokine‑induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

Authors:
- Wei Li
- Lin Ping Xu
- Ling Di Zhao
- Li Wang
- Yong Zhang
- Quan Li Gao
- Ling Mai
View Affiliations / Copyright

Affiliations: Department of Biotherapy, The Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, P.R. China, Department of Science Research, Henan Cancer Hospital, Zhengzhou 450003, P.R. China, Institute of Tumor Research, Henan Cancer Hospital, Zhengzhou 450003, P.R. China
Pages: 1427-1429
|
Published online on: February 19, 2013

https://doi.org/10.3892/ol.2013.1200
Expand metrics +

Abstract

Patients with advanced pancreatic adenocarcinoma have a poor prognosis, and to date, no treatment method has had a significant impact on the disease. In general, the mean overall survival time of such patients receiving conventional chemotherapy and radiotherapy is <6 months. In the present case report, a patient with advanced pancreatic adenocarcinoma experienced a longer progression‑free survival (PFS) of >19 months, following cytokine‑induced killer (CIK) cell therapy. To the best of our knowledge, no study has previously described such a beneficial effect on patients only receiving CIK cell immunotherapy. Based on these findings, CIK cell therapy may be a potential treatment regimen that is capable of leading to an improved prognosis in certain patients with advanced pancreatic adenocarcinoma.

View Figures

View References

1	Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 5:459–467. 2005. View Article : Google Scholar : PubMed/NCBI
2	Vizio B, Novarino A, Giacobino A, et al: Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med. 4:70–78. 2012.PubMed/NCBI
3	Franssen B and Chan C: Pancreatic Cancer: The surgeons point of view. Rev Gastroenterol Mex. 76:353–361. 2011.PubMed/NCBI
4	Janes RJ, Niederhuber JE, Chmiel JS, et al: National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg. 223:261–272. 1996. View Article : Google Scholar : PubMed/NCBI
5	Moss RA and Lee C: Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther. 3:111–127. 2010. View Article : Google Scholar : PubMed/NCBI
6	Koido S, Homma S, Takahara A, et al: Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011:2675392011. View Article : Google Scholar : PubMed/NCBI
7	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar
8	Hontscha C, Borck Y, Zhou H, et al: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
9	Schwaab T, Schwarzer A, Wolf B, et al: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 15:4986–4992. 2009.PubMed/NCBI
10	Liu L, Zhang W, Qi X, et al: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
11	Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
12	Werner J and Buchler MW: management of pancreatic cancer: recent advances. Dtsch Med Wochenschr. 136:1807–1810. 2011.PubMed/NCBI
13	Ng J, Zhang C, Gidea-Addeo D, et al: Locally advanced pancreatic adenocarcinoma: update and progress. JOP. 13:155–158. 2012.PubMed/NCBI
14	Cardenes HR, Chiorean EG, Dewitt J, et al: Locally advanced pancreatic cancer: current therapeutic approach. Oncologist. 11:612–623. 2006. View Article : Google Scholar : PubMed/NCBI
15	Karimi M, Cao TM, Baker JA, et al: Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 175:7819–7828. 2005.PubMed/NCBI
16	Verneris MR, Karami M, Baker J, et al: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004.PubMed/NCBI
17	Li R, Wang C, Liu L, et al: Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
18	Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
19	Joshi PS, Liu JQ, Wang Y, et al: Cytokine-induced killer T cells kill immature dendritic cells by tcr-independent and perforin-dependent mechanisms. J Leukoc Biol. 80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mesiano G, Todorovic M, Gammaitoni L, et al: Cytokine-induced killer (cik) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
21	Shi L, Zhou Q, Wu J, et al: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Cytokine‑induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

This article is mentioned in:

Abstract

Figure 1

Related Articles